Analyst Sees Increased Chance of Amylin (AMLN) Takeover Amid Bydureon Approval

January 30, 2012 2:52 PM EST
Get Alerts AMLN Hot Sheet
Price: $30.98 --0%

Rating Summary:
    3 Buy, 8 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AMLN Now!
Join SI Premium – FREE
Piper Jaffray's Ian Somaiya issued a note Monday morning suggesting FDA approval of Bydureon increases chances for a takeover of Amylin (Nasdaq: AMLN).

Amylin shares are up almost 17 percent this afternoon following the news. The stock last traded at $14.20.

Somaiya believes Amylin could be worth $33 per share based on an average multiple; applying a historic multiple which assumes peak sales gets the value into the $37-$49 per share range.

Piper Jaffray maintains an Overweight rating and $17 price target on shares of Amylin.

Track all the market-moving analyst calls on shares of Amylin with our Analyst Ratings page.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Piper Jaffray


lot less pain for diabetic patients.
on 2012-02-01 13:21:26
Mark as Spam | Reply to this comment

Instead of daily injections this drug allows once a week injection to diabetic patients. That is a great relief for them.

Mark as SPAM
Yvonne M Rayner on 2012-01-31 02:08:21
Mark as Spam | Reply to this comment

I'm not play game in this matter. I wish, you're take this matter SERIOUSLY. It's my first time to try to invest my money and you call me Spam. My e-mail address is;

How to buy share of Amylin Pharmaceutical
Yvonne M Rayner on 2012-01-31 01:51:29
Mark as Spam | Reply to this comment

Please send us the information, how to Buy Share/Stock of Amylin Pharmaceutical ASAP.

Add Your Comment